Insider Selling: Scholar Rock (NASDAQ:SRRK) Insider Sells 12,246 Shares of Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) insider Akshay Vaishnaw sold 12,246 shares of Scholar Rock stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $49.57, for a total value of $607,034.22. Following the sale, the insider owned 630,542 shares of the company’s stock, valued at approximately $31,255,966.94. This trade represents a 1.91% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scholar Rock Price Performance

Shares of SRRK stock traded down $2.16 during trading on Monday, hitting $47.80. The company had a trading volume of 1,128,695 shares, compared to its average volume of 1,353,022. The stock’s 50-day moving average is $46.16 and its two-hundred day moving average is $42.03. The stock has a market capitalization of $5.49 billion, a price-to-earnings ratio of -13.94 and a beta of 0.68. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.41. Scholar Rock Holding Corporation has a 52 week low of $27.07 and a 52 week high of $51.63.

Scholar Rock (NASDAQ:SRRK) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.10. During the same quarter in the prior year, the business earned ($0.64) EPS. As a group, analysts predict that Scholar Rock Holding Corporation will post -3.13 EPS for the current fiscal year.

Institutional Trading of Scholar Rock

Several hedge funds have recently added to or reduced their stakes in SRRK. Values First Advisors Inc. boosted its position in Scholar Rock by 1.5% during the first quarter. Values First Advisors Inc. now owns 18,850 shares of the company’s stock valued at $927,000 after buying an additional 286 shares during the period. E. Ohman J or Asset Management AB boosted its holdings in Scholar Rock by 35.2% during the 1st quarter. E. Ohman J or Asset Management AB now owns 22,136 shares of the company’s stock valued at $1,088,000 after acquiring an additional 5,762 shares during the period. Invesco Ltd. grew its position in Scholar Rock by 21.0% during the 4th quarter. Invesco Ltd. now owns 82,462 shares of the company’s stock worth $3,632,000 after acquiring an additional 14,291 shares during the last quarter. Mercer Global Advisors Inc. ADV purchased a new position in Scholar Rock in the 4th quarter worth approximately $308,000. Finally, Mackenzie Financial Corp purchased a new position in Scholar Rock in the 4th quarter worth approximately $221,000. 91.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on SRRK. Wedbush upped their target price on shares of Scholar Rock from $56.00 to $58.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 1st. BMO Capital Markets lifted their price target on Scholar Rock from $50.00 to $70.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 4th. HC Wainwright reiterated a “buy” rating and set a $58.00 price objective on shares of Scholar Rock in a research report on Tuesday, March 3rd. JPMorgan Chase & Co. raised their price objective on Scholar Rock from $47.00 to $50.00 and gave the company an “overweight” rating in a report on Monday, March 16th. Finally, Truist Financial boosted their target price on Scholar Rock from $44.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Four investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $55.40.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).